Get started
Author

Rene Y. Prudente

Observed names: R Prudente, R Y Prudente, R. Prudente, Rene Prudente
OpenAlex ID: A5006279759
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
2015 · Andiliy Lai, Mehmet Kahraman, et al. · Journal of Medicinal Chemistry · 261
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 126
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · ACS Medicinal Chemistry Letters · 81
A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer
2004 · Wan-Ching Yen, Manny R. Corpuz, et al. · Clinical Cancer Research · 71
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
2006 · W-C Yen, R Y Prudente, et al. · British Journal of Cancer · 57
PDF
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
2015 · Steven P. Govek, Johnny Y. Nagasawa, et al. · Bioorganic & Medicinal Chemistry Letters · 50
Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma
2004 · Wan-ching Yen, Rene Y. Prudente, et al. · Breast Cancer Research and Treatment · 48
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
2018 · Johnny Nagasawa, Steven Govek, et al. · Journal of Medicinal Chemistry · 44
Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2017 · Xinqiang Huang, Jill Magnus, et al. · Molecular Cancer Therapeutics · 20
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
2018 · Steven P. Govek, Celine Bonnefous, et al. · Bioorganic & Medicinal Chemistry Letters · 10
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2019 · James D Joseph, Beatrice Darimont, et al. · eLife · 7
Author response: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 5
Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · Cancer Research · 3
Cooperative antitumor activity between the retinoid X receptor (RXR)-selective agonist bexarotene and EGFR-tyrosine kinase inhibitors in preclinical models of NSCLC
2006 · R. P. Bissonnette, B. Fan, et al. · Journal of Clinical Oncology · 1
Supplementary Methods and legends from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2023 · Xinqiang Huang, Jill Magnus, et al.
Supplementary Figure 1S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2023 · Xinqiang Huang, Jill Magnus, et al.
Supplementary Figure 4S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2023 · Xinqiang Huang, Jill Magnus, et al.
Supplementary Figure 2S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2023 · Xinqiang Huang, Jill Magnus, et al.
Supplementary Figure 3S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2023 · Xinqiang Huang, Jill Magnus, et al.
Data from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
2023 · Xinqiang Huang, Jill Magnus, et al.
Abstract A37: A novel class of selective estrogen receptor degraders display activity in pre-clinical models of ERα+ ovarian cancer
2013 · James D. Joseph, Beatrice Darimont, et al. · Clinical Cancer Research
Abstract P6-04-12: Novel selective estrogen receptors degraders regress tumors in pre-clinical models of endocrine-resistant breast cancer
2012 · JH Hager, B Darimont, et al. · Cancer Research
Abstract A7: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
2012 · Beatrice Darimont, Steven Govek, et al. · Clinical Cancer Research
Abstract A133: A novel class of selective estrogen receptor degraders regresses tumors in preclinical models of endocrine-resistant breast cancer.
2011 · Beatrice Darimont, Steven Govek, et al. · Molecular Cancer Therapeutics
66 The combination of taxol and a selective retinoid X-receptor ligand targretin® (LGD1069) prevents and overcomes acquired taxol resistance in breast carcinoma
2003 · Wan-Ching Yen, Rene Y. Prudente, et al. · Lung Cancer
Works count: 25
Citation count: 784
H-index: 10
I10-index: 10
Year
Topic
Type